Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol. Issue 1 (13th July 2019)

• Record Type: Journal Article
• Authors: Lin, Tiezhu; Dans, Kunny C; Muftuoglu, Ilkay Kilic; Meshi, Amit; Amador-Patarroyo, Manuel J; Cheng, Lingyun; Freeman, William R
• Is Part Of: British journal of ophthalmology. Volume 104:Issue 1(2020)
• Page Start: 58
• Page End: 63
• Publication Date: 2019-07-13
• Subjects: retina -- neovascularisation -- macula -- imaging -- treatment medical; Ophthalmology -- Periodicals; 617.7
• DOI: 10.1136/bjophthalmol-2018-313447
• Languages: English
• ISSNs: 0007-1161

Abstract

Abstract : Aim: To show the characteristics and outcomes of patients with neovascular age-related macular degeneration (nAMD) who had extended remission (ER) while on a pro re nata (PRN) treatment protocol. Methods: This was a retrospective case–control study of a consecutive series of patients with nAMD treated with a PRN antivascular endothelial growth factor (anti-VEGF) drug regimen. ER was defined as the absence of haemorrhage, intraretinal/subretinal fluid on optical coherence tomography and leakage on fluorescein angiography for 52 weeks after cessation of anti-VEGF therapy. Matching patients with nAMD who did not achieve ER were included as control group. Cox regression analysis was fitted to identify predictors of time to achieve ER and time to recurrence. A logistic regression analysis of baseline characteristics was used to identify predictors of achieving ER. Results: Of 830 eyes treated with anti-VEGF monotherapy, 77 (9.2%) eyes achieved ER during a median follow-up of 236 weeks (range 70–525 weeks). Cox regression analysis showed that ER was achieved earlier in eyes with isolated intraretinal fluid (HR, 2.05; 95% CI 1.929 to 4.520; p=0.045) at presentation. Logistic regression analysis showed that type 3 choroidal neovascularisation (OR, 0.090; 95% CI 0.021 to 0.382; p=0.001), thinner choroid (OR, 0.993; 95% CI 0.988 to 0.998; p=0.004) and absence of macular atrophy (OR, 0.233; 95% CI 0.065 to 0.839; p=0.026) at baseline increased the likelihood of achieving ER. Conclusion: ER is achievable in 9.2% of patients under PRN therapy for nAMD. At presentation with nAMD, anatomical features on retinal imaging may predict the likelihood of achieving ER and a shorter time to achieve ER.